Nov 2023
Meet us at SITC 2023 in San DiegoSITC Annual Meeting 2023: Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers
Click here to RegisterOct 2023
Zumutor Biologics Inc announces collaboration with Enzene BiosciencesZumutor Biologics Inc announces collaboration with Enzene Biosciences for it’s INABLR™ Antibody discovery platform
Click here to read the Press ReleaseOct 2023
Meet us at ESMO 2023 in MadridESMO CONGRESS 2023: Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008–patient transcriptome analysis
Click here to RegisterAug 2023
IND (Investigational New Drug) approval for our lead molecule, ZM008 by the USFDAZumutor is excited to share the news of an IND (Investigational New Drug) approval for our lead molecule, ZM008 by the USFDA.
Click here to read the Press ReleaseAug 2023
Zumutor Biologics Inc announces FDA clearance of IND application of ZM008Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers
Click here to read the Press ReleaseFeb 2023
Zumutor receives the US patent for its novel biologic ZM008Zumutor receives the US patent for its novel biologic ZM008
Link to Blog PostJan 2023
Attended JPM from 9th Jan 2023 to 12th Jan 2023Attended JPM from 9th Jan 2023 to 12th Jan 2023
Nov 2022
SITC in Nov 2022SITC in Nov 2022
ViewJune 2022
Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) ApplicationZumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application
Link to Blog PostJune 2022
Abrogation of natural killer cell check point pathwayAbrogation of natural killer cell check point pathway
Link to Blog PostJune 2022
Abstract to the 2022 ASCO Annual Meeting (June 3 - June 7, 2022)Abrogation of Natural Killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers
April 21-22
Virtual ePoster Presentation at the SITC Tumor Immune Microenvironment: A Holistic Approach Workshop, held April 21-22 at SDNovel therapeutic antibody targeting LLT1-CD161 interaction results in NK cell activation and immune reactive tumor microenvironment in solid cancers
Dec 2021
Zumutor Biologics Secures $6.2M for a Promising Oncology MoleculeSep 2020
Zumutor Biologics Announces Receipt of a Grant from The United States - India Science & Technology Endowment BoardFeb 2020
Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid TumorsJan 2020
Kavitha Iyer Rodrigues, Founder-CEO showcased Zumutor at the Bio Century reception at JPM 38th Annual Conference in San FranciscoDec 2019
Zumutor Biologics raises $ 4 million in Series A2 fundingZumutor Biologics raises $ 4 million in Series A2 funding
Link to Blog PostNov 2019
Kavitha Iyer Rodrigues, Founder-CEO presented at the National Foundation of Cancer Research Fall Meeting of Oncology Investors Conference on 12th and 13th November 2019 at New York CityVisit
Venue: at 1155 6th Ave, New York CityJune 2019
At BIO 2019 on June 6th – we made a presentation on Thursday, June 6th at 11:15AM EST at the Start-up Stadium Booth #3071Visit
Ramon Valencia, VP- Corporate Development and Strategy was our lead ([email protected])June 2019
Dr. Sunit Maity, our Director, Process Development was at BIO International at Philly between June 3rd and 6th at the International Pavilion, India Booth #3927Visit
Dr. Sunit Maity – [email protected] was available for one-on-one meetingsMay-June 2019
Our Founder & CEO, Kavitha Iyer Rodrigues and CSO, Dr. Maloy Ghosh were at ASCO, May 31st to 4th June at ChicagoVisit
Maloy Ghosh – [email protected] was available for one-on-one meetingsMay 2019
Our Founder & CEO, Ms Kavitha Iyer Rodrigues was at the 5th Annual Immuno-Oncology BD&L and Investment Forum on May 31st in Chicago for Partnering and Investment meetingsMay 2019
Our Founder & CEO, Ms Kavitha Iyer Rodrigues was at the Asia Pacific Week 2019 Conference in Berlin between 13th and 19th May 2019Dec 2018
Kavitha Iyer Rodrigues, CEO receives the “Women Transforming India 2018” award at Delhi on December 16, 2018 from the Vice President of IndiaVisit
http://www.zumutor.com/2018/12/kavitha-iyer-rodrigues-ceo-receives-the-women-transforming-india-2018-award-at-delhi-on-december-16-2018-from-the-vice-president-of-india/Nov 2018
Zumutor Biologics Awarded the BioExcellence Emerging Company Award in 2018 by the Karnataka State GovernmentVisit
http://www.zumutor.com/2018/12/zumutor-biologics-awarded-the-bioexcellence-emerging-company-award-in-2018-by-the-karnataka-state-government/Nov 2018
Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on 'Human Antibody Library Development for therapeutic monoclonal antibody products'at INNO 2018Visit
http://www.zumutor.com/2018/12/dr-maloy-ghosh-chief-scientific-officer-at-zumutor-biologics-inc-spoke-on-human-antibody-library-development-for-therapeutic-monoclonal-antibody-products-at-inno-2018/May 2018
Syngene International Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery ServicesVisit
http://zumutor.com/wp-content/uploads/2018/06/Zumutor-Syngene-Press-Release.pdfFeb 2017
Kavitha Iyer-Rodrigues: Molecular formula to successDec 2016
India’s biotech capital spreads its wingsNov 2016
Zumutor was at PEGS Europe, 31st October to 4th November, LisbonNov 2016
Zumutor was at PEGS Europe, 31st October to 4th November, Lisbon